Efficacy and Safety of Platelet-Rich Plasma for Patients With Meniscal Injury: A Systematic Review and Meta-analysis of Randomized Controlled Trials

富血小板血浆治疗半月板损伤患者的疗效和安全性:随机对照试验的系统评价和荟萃分析

阅读:1

Abstract

BACKGROUND: Platelet-rich plasma (PRP) is widely used to promote healing and improve function in various musculoskeletal injuries. However, the efficacy and safety of PRP for meniscal injury remain unclear. PURPOSE: To evaluate the effects of PRP in patients with meniscal injury. STUDY DESIGN: Systematic review; Level of evidence, 2. METHODS: A comprehensive search was conducted in PubMed, Embase, Cochrane Library, Web of Science, Wanfang, and CNKI databases. Randomized controlled trials comparing PRP with placebo or no additional treatment in adult patients with meniscal injury were included. Outcome measures included the visual analog scale for knee pain, Lysholm score, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Knee injury and Osteoarthritis Outcome Score (KOOS), treatment failure, and complications. Data were pooled using a random-effects model by incorporating the influence of heterogeneity. RESULTS: This meta-analysis included 18 randomized controlled trials involving a total of 1143 patients. The mean follow-up duration ranged from 3 to 12 months. PRP significantly reduced knee pain (mean difference [MD], -0.73; 95% CI, -0.91 to -0.55) and improved knee function, as indicated by higher Lysholm scores (MD, 6.77; 95% CI, 5.35 to 8.20) and KOOS (MD, 4.34; 95% CI, 1.35 to 7.32), and lower WOMAC scores (MD, -5.33; 95% CI, -8.10 to -2.56). Subgroup analyses suggested similar results in patients with and without concurrent knee osteoarthritis, with single and multiple PRP injection, and with follow-up duration of <12 and ≥12 months. In addition, PRP also reduced treatment failure rates (odds ratio, 0.26; 95% CI, 0.12 to 0.59), with no significant difference in complications. CONCLUSION: PRP is effective in reducing pain and improving knee function in patients with meniscal injury. REGISTRATION: CRD42024601679 (PROSPERO).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。